Silvana Mourón

1.9k total citations
45 papers, 1.3k citations indexed

About

Silvana Mourón is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Silvana Mourón has authored 45 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 16 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Silvana Mourón's work include Cancer, Hypoxia, and Metabolism (9 papers), Cervical Cancer and HPV Research (8 papers) and Advanced Breast Cancer Therapies (6 papers). Silvana Mourón is often cited by papers focused on Cancer, Hypoxia, and Metabolism (9 papers), Cervical Cancer and HPV Research (8 papers) and Advanced Breast Cancer Therapies (6 papers). Silvana Mourón collaborates with scholars based in Spain, Argentina and United States. Silvana Mourón's co-authors include Juan Méndez, Carlos Daniel Golijow, María I. Martínez-Jiménez, Luis Blanco, Fernando Noel Dulout, Sara Rodríguez‐Acebes, Miguel Quintela-Fandiño, Aurelio Reyes, Gloria Terrados and Christopher A. Powell and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Molecular Cell.

In The Last Decade

Silvana Mourón

42 papers receiving 1.3k citations

Peers

Countries citing papers authored by Silvana Mourón

Since Specialization

Citations

This map shows the geographic impact of Silvana Mourón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvana Mourón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvana Mourón more than expected).

Fields of papers citing papers by Silvana Mourón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvana Mourón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvana Mourón. The network helps show where Silvana Mourón may publish in the future.

Co-authorship network of co-authors of Silvana Mourón

This figure shows the co-authorship network connecting the top 25 collaborators of Silvana Mourón. A scholar is included among the top collaborators of Silvana Mourón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvana Mourón. Silvana Mourón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The automated computational workflow QUICHE reveals structural definitions of antitumor responses in triple-negative breast cancer 2026 ·Nature Cancer ·(unknown), Noah F. Greenwald, (unknown), (unknown), C. H. Sowers, Alex Kong, Silvana Mourón, Miguel Quintela-Fandiño, (unknown), Sean C. Bendall, (unknown)	0
2	Abstract PO4-05-09: Phase I study of the FGFR inhibitor rogaratinib, fulvestrant and palbociclib in advanced hormone receptor-positive (HR+) breast cancer (BC) with FGFR1/2 amplification and/or overexpression (FGFR1/2+) 2024 ·Cancer Research ·Noelia Martínez-Jáñez, Sònia Pernas, José Á. García-Sáenz, Serafín Morales, Begoña Bermejo, Juan Antonio Guerra, Silvana Mourón, Miguel Quintela-Fandiño	2
3	Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement 2023 ·EClinicalMedicine ·Rámón Colomer, Jesús Miranda, Nuria Romero-Laorden, Javier Hornedo, Lucía González‐Cortijo, Silvana Mourón, María J. Bueno, Rebeca Mondéjar, Miguel Quintela-Fandiño	24
4	p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer 2023 ·JNCI Cancer Spectrum ·Silvana Mourón, María J. Bueno, Manuel Muñoz, Raúl Torres, Sandra Rodríguez, (unknown), Jorge Silva, Rodrigo Sánchez-Bayona, Luís Manso, Juan Antonio Guerra, (unknown), (unknown), Marcos Malumbres, Miguel Quintela-Fandiño	1
5	Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation 2023 ·Clinical & Translational Oncology ·María J. Bueno, Silvana Mourón, Eduardo Caleiras, (unknown), Luís Manso, Rámón Colomer, Miguel Quintela-Fandiño	0
6	Monitoring vascular normalization: new opportunities for mitochondrial inhibitors in breast cancer 2021 ·Oncoscience ·Silvana Mourón, María J. Bueno, Manuel Muñoz, (unknown)	1
7	Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer 2019 ·Clinical Cancer Research ·Miguel Quintela-Fandiño, Serafín Morales, (unknown), Luís Manso, (unknown), Manuel Muñoz, (unknown), (unknown), María Gión, Antonio López‐Alonso, Javier Cortés, Juan Antonio Guerra, (unknown), Eduardo Caleiras, Francisca Mulero, Silvana Mourón	32
8	Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition 2019 ·Breast Cancer Research ·Miguel Quintela-Fandiño, (unknown), (unknown), Silvana Mourón, Javier Hornedo, Lucía González‐Cortijo, Rámón Colomer, Juan Antonio Guerra	20
9	Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers 2018 ·Annals of Oncology ·Miguel Quintela-Fandiño, (unknown), Élise Martin, Manuel Moreno, Serafín Morales, B. Bermejo De Las Heras, (unknown), Rámón Colomer, Lucía González Cortijo, Javier Hornedo, Silvana Mourón, Manuel Muñoz, (unknown), Roberto Blanco Sequeiros, Santos Mañes	5
10	Uncoupling fork speed and origin activity to identify the primary cause of replicative stress phenotypes 2018 ·Journal of Biological Chemistry ·Sara Rodríguez‐Acebes, Silvana Mourón, Juan Méndez	35
11	Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach 2017 ·British Journal of Cancer ·María J. Bueno, Silvana Mourón, Miguel Quintela-Fandiño	29
12	PrimPol, an Archaic Primase/Polymerase Operating in Human Cells 2013 ·Molecular Cell ·(unknown), Aurelio Reyes, María I. Martínez-Jiménez, E. Sandra Chocrón, Silvana Mourón, Gloria Terrados, Christopher A. Powell, Eduardo Salido, Juan Méndez, Ian Holt, Luis Blanco	316
13	Repriming of DNA synthesis at stalled replication forks by human PrimPol 2013 ·Nature Structural & Molecular Biology ·Silvana Mourón, Sara Rodríguez‐Acebes, María I. Martínez-Jiménez, (unknown), (unknown), Luis Blanco, Juan Méndez	248
14	Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy 2011 ·Human Molecular Genetics ·Olga Criado‐García, Carmen Aguado, Javier Machín Gayarre, (unknown), Ana M. García-Cabrero, Santiago Vernia, Beatriz San Millán, Miguel López de Heredia, Carlos Romá‐Mateo, Silvana Mourón, (unknown), Mercedes Domínguez, Carmen Navarro, José M. Serratosa, Marina P. Sánchez, Pascual Sanz, Paola Bovolenta, Erwin Knecht, Santiago Rodrı́guez de Córdoba	117
15	Induction of DNA strand breaks, DNA-protein crosslinks and sister chromatid exchanges by arsenite in a human lung cell line 2005 ·Toxicology in Vitro ·Silvana Mourón, Claudia A. Grillo, Fernando Noel Dulout, Carlos Daniel Golijow	22
16	Detection ofc-erbB-2Gene Amplification in Cervical Scrapes Positive for Human Papillomavirus (HPV) 2001 ·Cancer Investigation ·Carlos Daniel Golijow, Martı́n C. Abba, Silvana Mourón, (unknown), (unknown), F.N. Dulout	7
17	c-myc gene amplification detected in preinvasive intraepithelial cervical lesions 2001 ·International Journal of Gynecological Cancer ·Carlos Daniel Golijow, Martı́n C. Abba, Silvana Mourón, (unknown), F.N. Dulout	17
18	DNA damage by cadmium and arsenic salts assessed by the single cell gel electrophoresis assay 2001 ·Mutation Research/Genetic Toxicology and Environmental Mutagenesis ·Silvana Mourón, Carlos Daniel Golijow, Fernando Noel Dulout	69
19	Association between activated K-ras and c-erbB-2 oncogenes with “high-risk” and “low-risk” Human Papilloma Virus types in preinvasive cervical lesions 2000 ·Mutation Research/Genetic Toxicology and Environmental Mutagenesis ·Silvana Mourón, Martı́n C. Abba, (unknown), (unknown), Fernando Noel Dulout, Carlos Daniel Golijow	15
20	Differences in K-ras Codon 12 Mutation Frequency between “High-Risk” and “Low-Risk” HPV-Infected Samples 1999 ·Gynecologic Oncology ·Carlos Daniel Golijow, Silvana Mourón, (unknown), F.N. Dulout	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact